Successful Partnership Between CSL Behring And Accovion Leads To Marketing Authorization For Berinert(R)  
11/25/2009 8:37:11 AM

ESCHBORN, Germany--(BUSINESS WIRE)--Accovion supports CSL Behring in successfully obtaining marketing authorization for Berinert® Berinert®, a human C1 esterase inhibitor (C1-INH) for treating acute episodes of facial or abdominal hereditary angioedema (HAE) in adults and adolescents has obtained approval from the US Food and Drug Administration (FDA). HAE is a rare and serious autosomal dominant genetic disease caused by C1-INH deficiency. Symptoms include sudden onset of edema (swelling) of the face, abdomen, extremities, or the larynx (which can be life threatening). Berinert® is a unique new treatment option for HAE, being the first C1-INH to be licensed in the USA for treatment of acute attacks of HAE.